Loading
A phase 3 trial of Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab in endometrial cancer, run by AstraZeneca, now recruiting.
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer is a phase 3 interventional study registered as NCT06989112 by AstraZeneca, with 600 participants planned, started 2025-03-27 and due to reach its primary completion in 2029-01-19. Interventions recorded: Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
Shares Docetaxel, Topoisomerase-I inhibitors (and ADC payloads), Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Rilvegostomig, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
Shares Rilvegostomig, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Advanced or recurrent endometrial cancer, Docetaxel, Endometrial cancer, Carboplatin.
Shares Rilvegostomig, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).
Shares Rilvegostomig, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca.
Shares Rilvegostomig, Topoisomerase-I inhibitors (and ADC payloads), Endometrial cancer, AstraZeneca.
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Carboplatin.